<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/815C5EC7-FEF6-4146-BF01-A7601535C8A3"><gtr:id>815C5EC7-FEF6-4146-BF01-A7601535C8A3</gtr:id><gtr:name>University of Montreal</gtr:name><gtr:address><gtr:line1>3000, chemin de la Cote-Sainte-Catherine</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/815C5EC7-FEF6-4146-BF01-A7601535C8A3"><gtr:id>815C5EC7-FEF6-4146-BF01-A7601535C8A3</gtr:id><gtr:name>University of Montreal</gtr:name><gtr:address><gtr:line1>3000, chemin de la Cote-Sainte-Catherine</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/420FE4EB-0EB1-48C0-8BB6-F29C94BAC937"><gtr:id>420FE4EB-0EB1-48C0-8BB6-F29C94BAC937</gtr:id><gtr:firstName>Zameel</gtr:firstName><gtr:surname>Cader</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601887"><gtr:id>2F30D57F-713B-4C54-A4B0-A7766FE30A91</gtr:id><gtr:title>The Role of Glycyl-tRNA Synthetase in Neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601887</gtr:grantReference><gtr:abstractText>Degenerative disorders of the nervous system place a significant and increasing healthcare burden as the average age of the population rises. In order to develop effective treatments, an understanding of how these disorders arise is critical. Relatively rare inherited diseases such as spinal muscular atrophy are an ideal paradigm with the insights gained expected to be broadly applicable to common conditions such as Alzheimer?s and Parkinson?s Disease. 

We are studying a neurodegenerative disorder caused by mutations in the gene for Glycyl-tRNA Synthetase (GlyRS): an enzyme required by cells to ensure proteins are synthesised correctly from their genetic templates. However, motor nerves are particularly vulnerable to mutations in this enzyme. To understand why, we will examine the cells of mice to study how GlyRS mutations might change gene expression and affect motor nerve function. We will then examine the interactions of this ubiquitous enzyme with proteins that may be specific to motor nerves. Through determination of the atomic structures, the key parts of the enzyme mediating such interactions can be identified. 

This research will yield fresh insights into how neurons degenerate and why they are vulnerable. This will then form the basis of new treatments for these appalling disorders.</gtr:abstractText><gtr:technicalSummary>Glycyl-tRNA synthetase (GlyRS) is an essential enzyme for ensuring the fidelity of translation of the genetic code through ligation of glycine with its cognate tRNA. Several dominant mutations have been identified in GlyRS causing lower motor neuron disorders. A mouse model with a C201R GlyRS mutation has also been identified on the basis of a distal motor neuronopathy (grip-strength) phenotype. Our preliminary structure-function studies demonstrate that mutant GlyRS forms functional enzymes but activity, which may be increased or decreased, is not consistently correlated with the disease phenotype. Furthermore a GlyRS mutation, with increased enzyme activity, reduces survival of cultured neurons. 

The aim of the proposed study is to understand how GlyRS mutations lead to neurodegeneration. We hypothesize that toxicity is mediated by a neuron-specific intermediary protein and this will be explored using the C201R mouse. We have therefore designed this project with the following specific objectives: 

1. Characterisation of the C201R mouse a. Histopathology of peripheral nerves and neuromuscular junction b. Motor neuron culture transfection studies c. Gene expression profiling to reveal gene networks leading to neurodegeneration 

2. Identifying GlyRS binding partners to reveal protein networks leading to neurodegeneration 

3. Structure-biochemistry of GlyRS-substrate complexes 

We will fully characterise the nature of the neurodegenerative process in C201R mice through electron microscopy and histopathology of peripheral nerves and muscle. Primary motor neuron cultures will be transfected with tagged axonal transport and synapse proteins and visualised with confocal microscopy. Changes in gene expression will be determined using DNA microarrays and real-time PCR. 

A yeast two-hybrid screen, co-immunoprecipitation and mass spectrometry will be used to identify binding partners. GlyRS will be crystallised in complex with cognate tRNA and binding partners using high-throughput sitting-drop vapour diffusion and structures determined with publicly available bioinformatics resources. This will be correlated with GlyRS enzyme activity in-vitro and in-vivo using standard radio-labelled aminoacylation assays. 

This project examines the neurodegenerative process from the most fundamental level of molecular architecture to the whole organism level. It represents a unique scientific opportunity to integrate several complementary disciplines; each placing the other in context and having the potential to provide greater insights into the mechanism of disease.

If the mechanism of toxicity in GlyRS mutations can be identified, drugs could be used to disrupt this process. GlyRS inhibitors already exist as do antibiotics targeting other aminoacyl-synthetases. Modification of these agents based upon structure-function work could eventually lead to effective treatments for neurodegenerative disorders.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>982130</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physics</gtr:department><gtr:description>TRESK - a new gene for migraine</gtr:description><gtr:id>B94E14AA-C7E6-4C82-967E-2EEAADBB1220</gtr:id><gtr:impact>Identification of the first gene linked to typical migraine - TRESK.
Publication in Nature Medicine
Significant media coverage of findings</gtr:impact><gtr:outcomeId>qwJjxqSuE7b-1</gtr:outcomeId><gtr:partnerContribution>This collaboration involved the electrophysiological characterization of TRESK in XenopusThe sequencing of migraine probands to identify variants in ion channel genes</gtr:partnerContribution><gtr:piContribution>Co-ordinating and leading collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Physiology, Anatomy and Genetics</gtr:department><gtr:description>A fly model of GlyRS Neurodegeneration</gtr:description><gtr:id>0FF8EA96-2E80-4937-B211-A7AE8218E2E2</gtr:id><gtr:impact>A validated fly model of neurodegeneration</gtr:impact><gtr:outcomeId>b7R68C4oUyb-1</gtr:outcomeId><gtr:partnerContribution>Generation of a fly model of Glycyl-tRNA synthetase to identify pathogenic mechanism and to understand interactions with other genes involved in neurodegeneration</gtr:partnerContribution><gtr:piContribution>Leading collaborative work</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>StemBANCC</gtr:description><gtr:id>938B8BD5-F07A-4C07-9E73-2F1B7820E901</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>hMVJcTZ9rdM-1</gtr:outcomeId><gtr:partnerContribution>25 academic institutions
10 pharmaceutical companies providing 26 million euros in-kind contribution</gtr:partnerContribution><gtr:piContribution>Leading this consortium</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>StemBANCC</gtr:description><gtr:id>4A5A5630-43F0-41B9-9FFA-4A338154DEDB</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>hMVJcTZ9rdM-2</gtr:outcomeId><gtr:partnerContribution>25 academic institutions
10 pharmaceutical companies providing 26 million euros in-kind contribution</gtr:partnerContribution><gtr:piContribution>Leading this consortium</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Montreal</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>TRESK - a new gene for migraine</gtr:description><gtr:id>A21DDB8E-E434-49B2-A43B-79F5F22D5873</gtr:id><gtr:impact>Identification of the first gene linked to typical migraine - TRESK.
Publication in Nature Medicine
Significant media coverage of findings</gtr:impact><gtr:outcomeId>qwJjxqSuE7b-2</gtr:outcomeId><gtr:partnerContribution>This collaboration involved the electrophysiological characterization of TRESK in XenopusThe sequencing of migraine probands to identify variants in ion channel genes</gtr:partnerContribution><gtr:piContribution>Co-ordinating and leading collaboration.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Mechanisms of Migraine, Migraine Trust Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6D7A8512-9302-4D4A-B296-CAB57308AE05</gtr:id><gtr:impact>100 migraine and headache sufferers attended a talk on the mechanisms of migraine. There was a question and answer session following the talk

There was significant interest in the talk such that other patient groups have subsequently requested further talks</gtr:impact><gtr:outcomeId>nuozBHQqN55</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRESK and Migraine Breaking News</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2DEEA7F0-6DC8-41FD-837C-CFEBC1DF0CBA</gtr:id><gtr:impact>Widespread coverage of Nature Medicine publication by newspapers, radio and TV worldwide

Numerous emails and other communications with congratulations or requests of interest to participate in research</gtr:impact><gtr:outcomeId>rCwKCc9Ssqu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>Oxford University John Fell Fund Award</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>91E15EEE-2347-4DBC-A69A-739A870FC59B</gtr:id><gtr:outcomeId>E7ECED2F51C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>James Martin Fund</gtr:department><gtr:description>OSCI Seed Funding (James Martin Fund)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>BC520E32-92CF-411E-8D86-B4BCECAF493B</gtr:id><gtr:outcomeId>XzGWVe3vXDB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>IMI</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4CE480F4-74C4-4364-88D6-E98024749BD2</gtr:id><gtr:outcomeId>ESv8vWdK24y</gtr:outcomeId><gtr:sector>Multiple</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Project Grants</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>F31E3911-DD4C-4662-AEE7-ED3B072B2E59</gtr:id><gtr:outcomeId>mjCRGsgNivb</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A lentiviral transduced NSC-34 cell line expressing Tet-ON GARS. Mitochondrial and cytoplasmic as well as wild-type and mutant isoforms</gtr:description><gtr:id>CEA24230-DA92-4F8A-B745-C14909626931</gtr:id><gtr:impact>This has allowed the characterization of the GARS transcriptome and proteome</gtr:impact><gtr:outcomeId>mWysQbViuoW</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>An inducible GARS neuronal stable cell line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Flies expressing human GARS - wildtype and disease causing mutants</gtr:description><gtr:id>34090DF6-9AEF-4D67-8BBC-C05E0219C553</gtr:id><gtr:impact>This has provide significant insights into the time course of the neuro-degenerative process and convergence points for genetic interactors</gtr:impact><gtr:outcomeId>EGZKyMBkRBz</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A Fly model of Glycyl-tRNA Synthetase</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Panel of cell lines from range of neurological and psychiatric disorders as well as diabetes and healthy controls.</gtr:description><gtr:id>A3DF10F4-D48C-4F60-AE9D-AF354CB99694</gtr:id><gtr:impact>This will become accessbile to the international research community</gtr:impact><gtr:outcomeId>Yu48AQroV6x</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stem Cell Resources</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://stembancc.org/</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7AD8BE1E-0C48-4CEC-82D6-DF65AB162C66</gtr:id><gtr:title>Plexin-Semaphorin Signaling Modifies Neuromuscular Defects in aModel of Peripheral Neuropathy.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d63de9fae35bc3ee7c117e337fcd52"><gtr:id>42d63de9fae35bc3ee7c117e337fcd52</gtr:id><gtr:otherNames>Grice SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5aa2baf4697a39.61238133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA2897EA-46F1-4F72-B821-D9B704E76235</gtr:id><gtr:title>The molecular pathogenesis of migraine: new developments and opportunities.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f60e5c83757bfd04413163f494b9aa9c"><gtr:id>f60e5c83757bfd04413163f494b9aa9c</gtr:id><gtr:otherNames>Zameel Cader M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_16167_27_23922230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>352D4C5B-2568-47FF-A51F-FEFA2EE789C4</gtr:id><gtr:title>HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fcd57c944de28bf8508684a8c28c3f"><gtr:id>89fcd57c944de28bf8508684a8c28c3f</gtr:id><gtr:otherNames>Benoy V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5aa2b9d08cac54.80028445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C097409-1155-4A25-A086-5A66A27DB542</gtr:id><gtr:title>New directions in migraine.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d60561b5dff9334d7daf25cd40679b7"><gtr:id>6d60561b5dff9334d7daf25cd40679b7</gtr:id><gtr:otherNames>Weir GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>bkjf7tTQVCS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2CB5B02-CECA-46AF-9F52-A6F940EA421D</gtr:id><gtr:title>Aligned electrospun fibers for neural patterning.</gtr:title><gtr:parentPublicationTitle>Biotechnology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4a0f645f776ae3bdcd2a0ee4553f9e4"><gtr:id>a4a0f645f776ae3bdcd2a0ee4553f9e4</gtr:id><gtr:otherNames>Soliman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0141-5492</gtr:issn><gtr:outcomeId>5aa2b9d1c4c623.51164327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0368CA5-A0A8-4EEE-994C-D651C2A8B921</gtr:id><gtr:title>Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds.</gtr:title><gtr:parentPublicationTitle>Genetic epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/121839c59892e14d8bdb64d0bb2ca23b"><gtr:id>121839c59892e14d8bdb64d0bb2ca23b</gtr:id><gtr:otherNames>Gay?n J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0741-0395</gtr:issn><gtr:outcomeId>V5fJ7TzkCER</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ACE56C1-8B32-45DE-9EF2-926953C9EC5D</gtr:id><gtr:title>An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e78549a28b33ad69cc45ce2d814a8585"><gtr:id>e78549a28b33ad69cc45ce2d814a8585</gtr:id><gtr:otherNames>Achilli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>B748D573871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD0238AB-24A1-4662-A845-E4E5E71C50ED</gtr:id><gtr:title>Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused bymutations.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2429b632bedd79bf4ea4a09b0209d4fb"><gtr:id>2429b632bedd79bf4ea4a09b0209d4fb</gtr:id><gtr:otherNames>Sleigh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5aa2b9d240d964.19216511</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CD34566-CD87-437A-B80D-267528F613D3</gtr:id><gtr:title>A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a223e0bf059ea3bbc87921fa0af3623"><gtr:id>8a223e0bf059ea3bbc87921fa0af3623</gtr:id><gtr:otherNames>Lafreni?re RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>GRJTrgSTwtE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>529D82D1-276E-43A9-9FE2-D7E417BFC9A7</gtr:id><gtr:title>Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2429b632bedd79bf4ea4a09b0209d4fb"><gtr:id>2429b632bedd79bf4ea4a09b0209d4fb</gtr:id><gtr:otherNames>Sleigh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5464a4a64f83b2.64217040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04AC2B23-53AB-44F6-8674-D4A316AB1352</gtr:id><gtr:title>Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/886b3e6aa85103d0bc4dce2eeb2374a7"><gtr:id>886b3e6aa85103d0bc4dce2eeb2374a7</gtr:id><gtr:otherNames>Janssen BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>pm_16167_27_23104057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAC0467A-0DF7-49D0-BDCE-7B665E690FC3</gtr:id><gtr:title>Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32711005bbbc3c895889b86f934b0688"><gtr:id>32711005bbbc3c895889b86f934b0688</gtr:id><gtr:otherNames>Cader MZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>31E051C3628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B87B450-7219-489E-81B4-F0F5E784F219</gtr:id><gtr:title>Dominant, toxic gain-of-function mutations in gars lead to non-cell autonomous neuropathology.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d63de9fae35bc3ee7c117e337fcd52"><gtr:id>42d63de9fae35bc3ee7c117e337fcd52</gtr:id><gtr:otherNames>Grice SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56e1137914d0b5.94068841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BC92BF2-E5DC-42FF-A29D-C33ED137BDD3</gtr:id><gtr:title>Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2429b632bedd79bf4ea4a09b0209d4fb"><gtr:id>2429b632bedd79bf4ea4a09b0209d4fb</gtr:id><gtr:otherNames>Sleigh JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>5464a4a62b83c9.30821163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8662958A-FFBF-45E8-B838-6E3FC64C217A</gtr:id><gtr:title>Engineered method for directional growth of muscle sheets on electrospun fibers.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical materials research. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4a0f645f776ae3bdcd2a0ee4553f9e4"><gtr:id>a4a0f645f776ae3bdcd2a0ee4553f9e4</gtr:id><gtr:otherNames>Soliman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-3296</gtr:issn><gtr:outcomeId>5aa2b9d1eaf2f5.20021699</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601887</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>